See more : THK Co., Ltd. (THKLF) Income Statement Analysis – Financial Results
Complete financial analysis of Amplia Therapeutics Limited (ATX.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amplia Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Korea Environment Technology Co., LTD. (029960.KQ) Income Statement Analysis – Financial Results
- Shah Metacorp Limited (SHAH.BO) Income Statement Analysis – Financial Results
- Ligand Pharmaceuticals Incorporated (LGNDV) Income Statement Analysis – Financial Results
- Meliá Hotels International, S.A. (MEL.MC) Income Statement Analysis – Financial Results
- Züblin Immobilien Holding AG (0REW.L) Income Statement Analysis – Financial Results
Amplia Therapeutics Limited (ATX.AX)
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.45M | 1.19M | 1.98M | 1.53M | 34.23K | 50.47K | 580.29K | 1.80M | 2.26M | 30.31K | 0.00 | 0.00 |
| Cost of Revenue | 441.99K | 73.37K | 3.21K | 672.00 | 801.00 | 1.59K | 20.16K | 36.95K | 568.42K | 237.99K | 167.28K | 236.53K |
| Gross Profit | 4.01M | 1.12M | 1.98M | 1.53M | 33.43K | 48.88K | 560.13K | 1.76M | 1.69M | -207.68K | -167.28K | -236.53K |
| Gross Profit Ratio | 90.07% | 93.83% | 99.84% | 99.96% | 97.66% | 96.85% | 96.53% | 97.94% | 74.89% | -685.21% | 0.00% | 0.00% |
| Research & Development | 5.80M | 4.69M | 3.77M | 2.21M | 1.07M | 678.42K | 3.22M | 6.04M | 4.75M | 2.04M | 648.00K | 773.39K |
| General & Administrative | 2.60M | 2.20M | 1.64M | 1.13M | 858.89K | 1.11M | 1.43M | 2.39M | 1.48M | 1.60M | 1.75M | 726.96K |
| Selling & Marketing | 86.00K | 516.64K | 215.58K | 527.83K | 327.75K | 244.40K | 192.31K | 297.18K | 271.21K | 139.76K | 51.91K | 213.58K |
| SG&A | 2.69M | 2.72M | 1.85M | 1.66M | 1.19M | 1.25M | 1.58M | 2.90M | 2.00M | 1.60M | 1.75M | 940.54K |
| Other Expenses | -58.95K | 1.19M | 1.98M | 1.59M | 34.23K | 50.47K | 642.84K | 1.83M | 2.29M | 30.00K | 28.00K | 0.00 |
| Operating Expenses | 8.44M | 7.40M | 5.62M | 3.87M | 2.26M | 1.92M | 4.81M | 8.93M | 6.74M | 5.43M | 4.09M | 2.58M |
| Cost & Expenses | 8.88M | 7.48M | 5.63M | 3.88M | 2.26M | 1.93M | 4.83M | 8.97M | 7.31M | 5.43M | 4.09M | 2.82M |
| Interest Income | 145.10K | 97.25K | 616.00 | 1.29K | 3.72K | 20.28K | 26.97K | 61.19K | 74.27K | 162.00K | 58.00K | 572.26K |
| Interest Expense | 78.48K | 53.85K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00 | 12.00 | 493.00K | 0.00 |
| Depreciation & Amortization | 86.15K | 73.37K | 3.21K | 672.00 | 801.00 | 1.59K | 20.16K | 36.95K | 568.42K | 1.55M | 1.48M | 1.33M |
| EBITDA | -4.56M | -7.26M | -3.64M | -2.34M | -2.22M | -1.89M | -4.30M | -7.10M | -4.45M | -3.69M | -2.62M | -1.48M |
| EBITDA Ratio | -102.40% | -622.28% | -283.55% | -252.65% | -6,598.07% | -3,813.35% | -828.17% | -496.75% | -297.92% | -12,804.78% | 0.00% | 0.00% |
| Operating Income | -4.42M | -7.48M | -5.63M | -3.88M | -2.26M | -1.93M | -4.83M | -8.97M | -7.31M | -5.40M | -4.09M | -3.03M |
| Operating Income Ratio | -99.38% | -628.45% | -283.72% | -252.69% | -6,600.40% | -3,816.50% | -831.65% | -498.80% | -323.04% | -17,810.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.52M | 84.46K | -1.15K | 60.40K | 5.41K | 5.91K | 528.39K | 1.89M | 74.26K | 161.67K | -434.77K | -357.56K |
| Income Before Tax | -8.94M | -7.39M | -5.63M | -3.81M | -2.25M | -1.92M | -4.30M | -8.87M | -7.21M | -5.24M | -4.50M | -3.39M |
| Income Before Tax Ratio | -200.80% | -621.35% | -283.74% | -248.75% | -6,584.57% | -3,804.79% | -740.59% | -493.54% | -318.40% | -17,278.70% | 0.00% | 0.00% |
| Income Tax Expense | -4.44M | -1.15M | -1.98M | -1.53M | -34.23K | -50.47K | -2.00 | -1.80M | -2.26M | -162.00K | 521.00K | 0.00 |
| Net Income | -4.50M | -6.24M | -3.64M | -2.28M | -2.22M | -1.87M | -4.30M | -7.08M | -4.94M | -5.24M | -4.50M | -3.39M |
| Net Income Ratio | -101.14% | -524.80% | -183.74% | -148.75% | -6,484.57% | -3,704.79% | -740.59% | -393.54% | -218.40% | -17,278.70% | 0.00% | 0.00% |
| EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.04 | -0.04 | -0.17 | -0.30 | -0.24 | -0.27 | -0.34 | -0.20 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.02 | -0.04 | -0.04 | -0.17 | -0.30 | -0.24 | -0.27 | -0.34 | -0.20 |
| Weighted Avg Shares Out | 194.01M | 193.98M | 145.55M | 95.70M | 52.96M | 43.44M | 25.36M | 23.92M | 20.62M | 19.08M | 13.04M | 17.32M |
| Weighted Avg Shares Out (Dil) | 194.01M | 193.98M | 145.55M | 95.70M | 52.96M | 43.44M | 25.36M | 23.92M | 20.62M | 19.08M | 13.04M | 17.32M |
Source: https://incomestatements.info
Category: Stock Reports